CStone Pharmaceuticals’s Cejemly (Sugemalimab) Receives the EC’s Approval to Treat Non-Small Cell Lung Cancer
Shots:
- The EC has granted approval to Cejemly plus Pt-based CT as a 1L treatment of metastatic non-small-cell lung cancer (NSCLC) adults without EGFR mutations or ALK, ROS1 or RET genomic tumor aberrations
- The approval was based on P-III (GEMSTONE-302) trial that showed extended PFS & OS with Cejemly + Pt-based CT vs PBO among untreated NSCLC patients. Data was published in The Lancet Oncology as well as Nature Cancer & will be highlighted at ESMO 2024 (#1318P)
- In addition, the company is planning MAA submissions across various indications such as stage III NSCLC, 1L gastric cancer & esophageal cancer as well as r/r extranodal natural killer/T-cell lymphoma (r/r ENKTL)
Ref: CStone | Image: CStone
Related News:- CStone Pharmaceuticals’ Cejemly Receives the CHMP’s Positive Opinion for Treating NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
